Related Experiment Video
Updated: Jun 1, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis
Chiara Tommasi1, Rita Bellagamba, Massimo Tempestilli
1National Institute for Infectious Diseases L, Spallanzani, Via Portuense 292, 00149 Rome, Italy. chiara.tommasi@inmi.it
Abstract:
The case of a 32-year-old Caucasian female with multi-drug resistant HIV-1 subtype B infection treated with a salvage regimen including maraviroc, raltegravir, etravirine and unboosted saquinavir who started atovaquone/proguanil prophylaxis, is reported. The potential interactions between atovaquone/proguanil and these anti-retroviral drugs are investigated. Pharmacokinetic analyses documented a marked increase in etravirine and saquinavir plasma concentrations (+55% and +274%, respectively), but not in raltegravir and maraviroc plasma concentrations. The evidence that atovaquone/proguanil significantly interacts with etravirine and saquinavir, but not with raltegravir and maraviroc, suggests that the mechanism of interaction is related to cytochrome P450.
Related Concept Videos
Antiprotozoal Agents
Therapeutic Drug Monitoring: Affecting Factors
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Antiviral Nucleoside Inhibitors
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...

